ClinicalTrials.gg
CompletedNCT00168740Updated Sep 15, 2005

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

A Phase 3 interventional study of rituximab in Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma, sponsored by Biogen. Completed at 31 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-09-15.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 58 studies testing rituximab in Lymphoma, B-Cell — 8 open to participants now, 12 under way, 1 of them phase 3. Rituximab · Lymphoma, B-Cell.

Enrollment
7th of 58
150 · median 38
Started
1995
the only one that year
Phase 3
6 of 58
none open now
Registered
5th of 58
by date
Lead sponsor
1 of 58
Biogen

Among the 58 studies testing rituximab in Lymphoma, B-Cell, this one is the 7th largest by enrollment, is the only one that started in 1995, is one of 6 in phase 3, and was the 5th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 58 studies testing rituximab in Lymphoma, B-Cell are open now, in 9 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing rituximab in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

03

Conditions studied

  • Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Browse trials for

Keywords

  • rituximab
  • Rituxan
  • B-cell lymphoma
  • low-grade
  • follicular
  • anti-CD20 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of , low-grade or follicular B-cell lymphoma
  • CD20-positive lymphoma
  • Progressive,
  • Sign
  • 3 weeks beyond standard therapy
  • Good performance status
  • Adequate hematologic, renal, and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Chronic lymphocytic leukemia
  • Lesions greater than or equal to 10 cm in diameter
  • CNS lymphoma
  • AIDS-related lymphoma
  • Pleural effusions or ascites secondary to lymphoma
  • Active, opportunistic infection
  • Serious nonmalignant disease
  • Prior therapies, including prior anti-CD20 therapy
  • Recent major surgery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants

Interventions

06

What researchers measure

Primary outcomes

  1. overall response rate

Secondary outcomes

  1. time to disease progression

  2. progressive disease-free interval

07

Study locations

31 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States
  • City of Hope Natioal Medical Center
    Duarte, California, United States
  • Scripps Memorial Hospital
    La Jolla, California, United States
  • UCSD Stem Cell Laboratory
    La Jolla, California, United States
  • Hoag Hospital
    Newport Beach, California, United States
  • Sutter Cancer Center
    Sacramento, California, United States
  • Sidney Kimmel Cancer Center
    San Diego, California, United States
  • University of California, San Francisco
    San Francisco, California, United States
  • Stanford University Medical Center
    Stanford, California, United States
  • Kaiser Permanente Medical Center
    Vallejo, California, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado, United States
  • Georgetown University Medical Center
    Washington, District of Columbia, United States
  • Robert H. Lurie Cancer Center, Northwestern University
    Chicago, Illinois, United States
  • University of Iowa General Hospital
    Iowa City, Iowa, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky, United States
  • Louisiana State University
    Shreveport, Louisiana, United States
  • University of Maryland Cancer Center
    Baltimore, Maryland, United States
  • Michigan State University
    East Lansing, Michigan, United States
  • St. Louis University Medical Center
    St. Louis, Missouri, United States
  • Roswell Park Cancer Center
    Buffalo, New York, United States
  • University of Rochester Cancer Center
    Rochester, New York, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States
  • The West Clinic, P.C.
    Memphis, Tennessee, United States
  • Texas Oncology, P.A.
    Dallas, Texas, United States
  • M.D. Anderson Cancer Center
    Houston, Texas, United States
  • University of Texas Health Sciences Center
    San Antonio, Texas, United States
  • University of Virginia
    Charlottesville, Virginia, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
  • Ottawa General Hospital
    Ottawa, Ontario, Canada
  • Toronto-Sunnybrook Regional Cancer Center
    Toronto, Ontario, Canada
08

References and documents

Publications

  • McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. doi: 10.1200/JCO.1998.16.8.2825. PubMed 9704735 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00168740
Lead sponsor
Biogen
First posted
Sep 15, 2005
Start date
Apr 1995
Last update
Sep 15, 2005

Study contacts

Antonio J. Grillo-Lopez, M.D.
study director · Biogen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion